Adverse effects and antibody titers in response to the BNT162b2 mRNA COVID-19 vaccine in a prospective study of healthcare workers
| Autor: | Simon Pollett, Luca Illinik, Alyssa R. Lindrose, Emilie Goguet, Edward Parmelee, Allison M. W. Malloy, Orlando Ortega, Cara H. Olsen, Santina Maiolatesi, Emily C Samuels, Julian Davies, Edward Mitre, Monique Hollis-Perry, Matthew Moser, David R. Tribble, Mimi A Wong, Yolanda Alcorta, John H. Powers, Andrew L. Snow, Si'Ana A Coggins, Gregory Wang, Timothy Burgess, Belinda M. Jackson-Thompson, Anatalio E Reyes, Eric D Laing, Andrew G. Letizia, Christopher C. Broder, Kathleen F Ramsey, Christopher A. Duplessis |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
business.industry SARS-CoV-2 Antibody titer COVID-19 antibody titer Article Vaccination Clinical trial Editor's Choice Clinical research Infectious Diseases AcademicSubjects/MED00290 mRNA vaccine Oncology Internal medicine Major Article adverse effects Medicine business Prospective cohort study Adverse effect Cohort study Biomedical sciences |
| Zdroj: | Open Forum Infectious Diseases medRxiv |
| Popis: | Background The relationship between postvaccination symptoms and strength of antibody responses is unclear. The goal of this study was to determine whether adverse effects caused by vaccination with the Pfizer/BioNTech BNT162b2 vaccine are associated with the magnitude of vaccine-induced antibody levels. Methods We conducted a single-center, observational cohort study consisting of generally healthy adult participants that were not severely immunocompromised, had no history of coronavirus disease 2019, and were seronegative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein before vaccination. Severity of vaccine-associated symptoms was obtained through participant-completed questionnaires. Testing for immunoglobulin G antibodies against SARS-CoV-2 spike protein and receptor-binding domain was conducted using microsphere-based multiplex immunoassays performed on serum samples collected at monthly visits. Neutralizing antibody titers were determined by microneutralization assays. Results Two hundred six participants were evaluated (69.4% female, median age 41.5 years old). We found no correlation between vaccine-associated symptom severity scores and vaccine-induced antibody titers 1 month after vaccination. We also observed that (1) postvaccination symptoms were inversely correlated with age and weight and more common in women, (2) systemic symptoms were more frequent after the second vaccination, (3) high symptom scores after first vaccination were predictive of high symptom scores after second vaccination, and (4) older age was associated with lower titers. Conclusions Lack of postvaccination symptoms after receipt of the BNT162b2 vaccine does not equate to lack of vaccine-induced antibodies 1 month after vaccination. We found no correlation between BNT162b2-associated symptom severity and vaccine-induced antibody titers 1 month after vaccination. Adverse effects inversely correlated with age and weight, whereas symptom severity after first vaccination was predictive of that after second vaccination. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|